The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma–CLEAP 004 study

CX Yang, YX Pan, F Ye, XD Zhu, J Xue, X Li… - Frontiers in …, 2024 - frontiersin.org
Background For decades, stratification criteria for first-line clinical studies have been highly
uniform. However, there is no principle or consensus for restratification after systemic …
相关文章
[HTML] nih.gov

[HTML][HTML] The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma–CLEAP …

CX Yang, YX Pan, F Ye, XD Zhu, J Xue, X Li… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
Background For decades, stratification criteria for first-line clinical studies have been highly
uniform. However, there is no principle or consensus for restratification after systemic …

The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma-CLEAP 004 study.

CX Yang, YX Pan, F Ye, XD Zhu, J Xue, X Li… - Frontiers in …, 2024 - europepmc.org
Background For decades, stratification criteria for first-line clinical studies have been highly
uniform. However, there is no principle or consensus for restratification after systemic …

The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma-CLEAP 004 study

CX Yang, YX Pan, F Ye, XD Zhu… - Frontiers in …, 2024 - pubmed.ncbi.nlm.nih.gov
Background For decades, stratification criteria for first-line clinical studies have been highly
uniform. However, there is no principle or consensus for restratification after systemic …